Chimerix (CMRX) Ramps 8% as Cohen's Point72 Backs Up the Truck

Beaten down pharma company Chimerix (NASDAQ: CMRX) is surging 7.8% in pre-open trade after Steven Cohen's Point72 Asset Management, L.P. showed a new 2,454,943 share, or 5.3% stake, after the bell.

Intra-day Wednesday, notable insider buying was also disclosed.

Chimerix sank 81% Monday after at its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection through Week 24 after transplant.

You May Also Be Interested In

• BofA says there is a continued strength in buybacks
• Snap (SNAP), Meta (META) gain as House orders sale or ban of TikTok